Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PZ04 PD-1Ab21-CD19CAR-T cells
- Development stage
- Unknown
- Lead developer
- The First Medical Center of Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PZ04 PD-1Ab21-CD19CAR-T cells is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Chinese People's Liberation Army (PLA) General Hospital. The therapy is designed to treat CD19-positive hematological malignancies, including B-cell lymphomas and leukemias. These CAR-T cells are engineered to target the CD19 antigen on malignant B cells and are further modified to express or secrete a PD-1 antibody (PD-1Ab21). This dual approach aims to directly eliminate tumor cells while simultaneously blocking the PD-1/PD-L1 inhibitory pathway, which often leads to T-cell exhaustion and treatment failure in the tumor microenvironment. PZ04 is currently being investigated in early-phase clinical trials to assess its safety, efficacy, and in vivo expansion.
- Other names
- PZ04 PD-1Ab21-CD19CAR-T cellsPZ-04 PD-1Ab21-CD19CAR-T cellsPZ 04 PD-1Ab21-CD19CAR-T cellsPD-1Ab21-CD19CAR-T cellsPD1Ab21-CD19CAR-T cellsPD 1Ab21-CD19CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on PZ04 PD-1Ab21-CD19CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PZ04 PD-1Ab21-CD19CAR-T cells.